BTIG Expands Healthcare Research Team with Biotechnology Analyst Ling Wang

www.btig.com

NEW YORK--()--BTIG, LLC, a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services, announced today that Ling Wang, CFA has joined the firm as a Director and Biotechnology Research Analyst in New York.

“Complementing the diverse and rapidly expanding healthcare research coverage of our other team members, Ling greatly enhances BTIG’s expertise in the biotechnology space”

Ms. Wang has more than 15 years of experience in biotechnology research, having analyzed companies within the sector for several global financial services firms in a variety of roles. Most recently, she was a Senior Research Analyst at Oppenheimer & Co. Earlier in her career, she conducted research at Memorial Sloan-Kettering Cancer Center, participating in clinical trials as part of a team that evaluated cancer vaccines. At BTIG, Ms. Wang’s coverage will focus on biotechnology companies, industry trends and the competitive landscape. Biotechnology research represents an important focus within the firm’s healthcare research offering.

“Complementing the diverse and rapidly expanding healthcare research coverage of our other team members, Ling greatly enhances BTIG’s expertise in the biotechnology space,” said Karen Blando, Managing Director and Director of Research at BTIG. “Ling’s experience evaluating biotechnology companies, across broad therapeutic areas in pre-clinical and clinical programs, will be tremendously valuable to our clients.”

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 500 employees, BTIG, LLC and its affiliates operate out of 14 cities in North America, Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs, fixed income, futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities. The company’s core capabilities include global sales, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer: https://www.btig.com/Disclaimer.aspx

Contacts

For BTIG, LLC
Jill Gordon, 212-279-3115 x226
jgordon@prosek.com
or
Amanda Gold, 212-738-6134
agold@btig.com

Recent Stories

RSS feed for BTIG, LLC